Related Experiment Video
Updated: Jul 7, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Targeting Longevity Gene SLC13A5: A Novel Approach to Prevent Age-Related Bone Fragility and Osteoporosis
Grit Zahn1, Hannes A Baukmann2, Jasmine Wu3
1Eternygen GmbH, Westhafenstrasse 1, 13353 Berlin, Germany.
Abstract:
Reduced expression of the plasma membrane citrate transporter SLC13A5, also known as INDY, has been linked to increased longevity and mitigated age-related cardiovascular and metabolic diseases. Citrate, a vital component of the tricarboxylic acid cycle, constitutes 1-5% of bone weight, binding to mineral apatite surfaces. Our previous research highlighted osteoblasts' specialized metabolic pathway facilitated by SLC13A5 regulating citrate uptake, production, and deposition within bones. Disrupting this pathway impairs bone mineralization in young mice. New Mendelian randomization analysis using UK Biobank data indicated that SNPs linked to reduced SLC13A5 function lowered osteoporosis risk. Comparative studies of young (10 weeks) and middle-aged (52 weeks) osteocalcin-cre-driven osteoblast-specific Slc13a5 knockout mice (Slc13a5cKO) showed a sexual dimorphism: while middle-aged females exhibited improved elasticity, middle-aged males demonstrated enhanced bone strength due to reduced SLC13A5 function. These findings suggest reduced SLC13A5 function could attenuate age-related bone fragility, advocating for SLC13A5 inhibition as a potential osteoporosis treatment.
Insights
Reduced expression of the citrate transporter SLC13A5 (INDY) may protect against bone fragility and osteoporosis. Lowering SLC13A5 function in middle-aged mice improved bone strength and elasticity, suggesting therapeutic potential.
Area of Science:
- Bone Biology
- Metabolic Regulation
- Aging Research
Background:
- The citrate transporter SLC13A5 (INDY) plays a role in bone metabolism and mineralization.
- Reduced SLC13A5 expression is associated with longevity and protection against metabolic and cardiovascular diseases.
- Osteoblasts utilize SLC13A5 for citrate regulation, crucial for bone health.
Purpose of the Study:
- To investigate the role of SLC13A5 in age-related bone fragility.
- To evaluate the therapeutic potential of inhibiting SLC13A5 for osteoporosis treatment.
Main Methods:
- Mendelian randomization analysis using UK Biobank data to assess the association between SLC13A5 function and osteoporosis risk.
- Comparative study of young and middle-aged osteoblast-specific Slc13a5 knockout mice (Slc13a5) to evaluate bone properties.
Main Results:
- Mendelian randomization indicated that single nucleotide polymorphisms (SNPs) linked to reduced SLC13A5 function were associated with lower osteoporosis risk.
- Middle-aged female Slc13a5 knockout mice showed improved bone elasticity.
- Middle-aged male Slc13a5 knockout mice exhibited enhanced bone strength.
- Disruption of the osteoblast SLC13A5 pathway impairs bone mineralization in young mice.
Conclusions:
- Reduced SLC13A5 function may attenuate age-related bone fragility.
- Inhibiting SLC13A5 presents a potential therapeutic strategy for treating osteoporosis.
